Evidence map›Paper›PMID 41217667›Full record

ReviewMedical oncology (Northwood, London, England)2025

Harnessing GSK-3β inhibition for lung cancer therapy: emerging opportunities and challenges.

Emad H M Hassanein, Hanan S Althagafy, Hanan H Abd- ElHafeez, Islam M Ibrahim, Badrah S Alghamdi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Emad H M HassaneinDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut, 71524, Egypt. emadhassanien@azhar.edu.eg.
Hanan S AlthagafyDivision of Biochemistry, Department of Biological Sciences, Faculty of Science, University of Jeddah, Jeddah, Saudi Arabia.
Hanan H Abd- ElHafeezDepartment of Anatomy and Histology, Faculty of Veterinary Medicine, Assiut University, Asyut, Egypt.
Islam M IbrahimDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Badrah S AlghamdiNeuroscience and Geroscience Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer (LC) primarily affects men and is the third most common cause of cancer-related death worldwide. Treatment for LC involves many phases, each with specific challenges arising from the characteristics of malignancy and the limitations of chemotherapy. GSK-3β, a serine/threonine kinase factor, is essential for several signals that control important cellular functions and a variety of diseases, including cancer. GSK-3β regulates transcription factors through phosphorylation, which in turn activates signaling pathways such as PI3K/AKT/mTOR, Wnt/β-catenin, and NF-κB. These signaling pathways might affect LC. Additionally, targeting GSK-3β offers a promising approach to overcoming drug resistance in cancer therapy. Inhibiting GSK-3β has been demonstrated to boost chemotherapy sensitivity, making cancer cells more responsive to treatment, while also suppressing their growth and survival. We provide an in-depth analysis of scientific literature that investigates the manner in which inhibiting GSK-3β with various compounds might be used to treat, impede, and improve the therapeutic response in LC cells. Next, we suggested that GSK-3β inhibition might be a therapeutic option to increase patient survival in patients with LC. For this reason, further studies on this subject will be required in the coming years.

Indexed as

Antineoplastic AgentsGlycogen Synthase Kinase 3 betaLung NeoplasmsProtein Kinase InhibitorsAnimalsHumansSignal TransductionAntineoplastic AgentsGlycogen Synthase Kinase 3 betaProtein Kinase InhibitorsGSK-3βLung cancerNSCLCPI3/AKT/mTORWnt/β-catenin

Identifiers

PMID41217667
PMCPMC12605635

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.